A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy
Phase of Trial: Phase II
Latest Information Update: 23 Dec 2018
At a glance
- Drugs Avacopan (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Therapeutic Use
- Sponsors ChemoCentryx
- 08 Nov 2018 According to a ChemoCentryx media release, enrolment in the study is now 61% complete for the initial cohort of 44 patients; 35% complete for the expanded study targeting a combined 88 patients.
- 06 Aug 2018 The trial has been suspended in Germany.
- 05 Jun 2018 Planned number of patients changed from 44 to 88.